Journal of the American Academy of Dermatology

Article	Citations
Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases	645
Immune checkpoint inhibitor–related dermatologic adverse events	256
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial	242
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies	170
Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis	169
Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures	154
Hand hygiene during COVID-19: Recommendations from the American Contact Dermatitis Society	149
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1	143
Oral minoxidil treatment for hair loss: A review of efficacy and safety	141
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 i	125
Skin color in dermatology textbooks: An updated evaluation and analysis	122
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results	117
Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study	114
United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019	108
Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agent	104
Visible light. Part I: Properties and cutaneous effects of visible light	102
Photoprotection beyond ultraviolet radiation: A review of tinted sunscreens	101
Prurigo nodularis	99
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)	93
Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review	92
Infantile hemangioma. Part 1: Epidemiology, pathogenesis, clinical presentation and assessment	91
COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence	89
Prurigo nodularis	88
Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis	85
The digital divide: How COVID-19's telemedicine expansion could exacerbate disparities	84

Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients	84
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations	84
Occupational dermatitis to facial personal protective equipment in health care workers: A systematic review	83
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19	83
The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study	80
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3	80
Facial and neck erythema associated with dupilumab treatment: A systematic review	79
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study	79
American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults	78
Guidelines of care for the management of actinic keratosis	76
The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: A systematic analysis from the Global Burden of Disease Study 2017	76
Association between alopecia areata, anxiety, and depression: A systematic review and meta-analysis	70
Cutaneous adverse events caused by immune checkpoint inhibitors	69
The ongoing racial disparities in melanoma: An analysis of the Surveillance, Epidemiology, and End Results database (1975-2016)	69
Infantile hemangioma. Part 2: Management	67
Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan	67
Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study	66
Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis	65
Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis	64
Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis	63
Visible light. Part II: Photoprotection against visible and ultraviolet light	62
Itch: Pathogenesis and treatment	61
Management of inadequate response and adverse effects to dupilumab in atopic dermatitis	60
The clinical spectrum of COVID-19–associated cutaneous manifestations: An Italian multicenter study of 200 adult patients	60
Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus	60
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis	60
Skin cancer: Primary, secondary, and tertiary prevention. Part I	58
Immune checkpoint inhibitors to treat cutaneous malignancies	57
Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group	57
Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma	56
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry	56
Hair transplantation: Basic overview	54
Role of phototherapy in the era of biologics	53
The impact of demographics, socioeconomics, and health care access on melanoma outcomes	52
Diagnostic and management considerations for “maskne” in the era of COVID-19	52
The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study	51
Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation	51
Treatment of pediatric alopecia areata: A systematic review	51
Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial	50
Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)	50
Axial psoriatic arthritis: An update for dermatologists	50
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study	49
Reflectance confocal microscopy	48
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial	47
Dermatology without dermatologists? Analyzing Instagram influencers with dermatology-related hashtags	47
Dermatologists in social media: A study on top influencers, posts, and user engagement	47
Isolated nail lichen planus: An expert consensus on treatment of the classical form	46
Itch: Epidemiology, clinical presentation, and diagnostic workup	46
Impact of visible light on skin health: The role of antioxidants and free radical quenchers in skin protection	44
Overview of TikTok's most viewed dermatologic content and assessment of its reliability	44

Representation of dark skin images of common dermatologic conditions in educational resources: A cross-sectional analysis	44
Mucocutaneous disease and related clinical characteristics in hospitalized children and adolescents with COVID-19 and multisystem inflammatory syndrome in children	43
Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata	43
Systemic sclerosis in adults. Part I: Clinical features and pathogenesis	43
TNF-α inhibitor–induced psoriasis: A decade of experience at the Cleveland Clinic	43
Bias in, bias out: Underreporting and underrepresentation of diverse skin types in machine learning research for skin cancer detection—A scoping review	43
Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial	43
Combination tofacitinib and oral minoxidil treatment for severe alopecia areata	42
Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis	42
Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial	42
The use of noninvasive imaging techniques in the diagnosis of melanoma: a prospective diagnostic accuracy study	42
Dermoscopic features of basal cell carcinoma and its subtypes: A systematic review	42
Association between rosacea and cardiometabolic disease: A systematic review and meta-analysis	42
Development of psoriasis during treatment with dupilumab: A systematic review	42
Guidelines of care for the management of acne vulgaris	42
Psoriasis and mortality in the United States: Data from the National Health and Nutrition Examination Survey	42
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1	41
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data	41
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial	41
An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology	41
Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study	41
Pain management in hidradenitis suppurativa and a proposed treatment algorithm	39
The magnitude of COVID-19's effect on the timely management of melanoma and nonmelanoma skin cancers	38
Participation bias, self-selection bias, and response bias	38
Improved patient access and outcomes with the integration of an eConsult program (teledermatology) within a large academic medical center	38
Insect repellents: An updated review for the clinician	38
Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign	37
Health-related quality of life and economic burden of prurigo nodularis	37
Neurofibromatosis type 1: New developments in genetics and treatment	37
The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches	37
Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry	37
Real-world comorbidities of atopic dermatitis in the pediatric ambulatory population in the United States	37
Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study	37
Association of atopic dermatitis severity with cognitive function in adults	37
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies	36
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial	36
Diagnostic performance of artificial intelligence for histologic melanoma recognition compared to 18 international expert pathologists	36
Time of onset and duration of post-COVID-19 acute telogen effluvium	36
Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: A systematic review of the literature	35
Monkeypox emerges on a global scale: A historical review and dermatologic primer	35
The Alopecia Areata Consensus of Experts (ACE) study part II: Results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata	35
The rule of 10s versus the rule of 2s: High complication rates after conventional excision with postoperative margin assessment of specialty site versus trunk and proximal extremity melanomas	35
Systematic review and meta-analysis of local recurrence rates of head and neck cutaneous melanomas after wide local excision, Mohs micrographic surgery, or staged excision	35
A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes	34
Janus kinase inhibitors in dermatology: Part I. A comprehensive review	34
Characterizing the role of dermatologists in developing artificial intelligence for assessment of skin cancer	34
Guidelines of care for the management of atopic dermatitis in adults with topical therapies	34
CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health	34
Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: A nationwide cancer registry study	34
Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist	34
Early ultrasound for diagnosis and treatment of vascular adverse events with hyaluronic acid fillers	34
Melanoma: An update on systemic therapies	34
The effect of platelet-rich plasma on female androgenetic alopecia: A randomized controlled trial	34
TikTok and dermatology: An opportunity for public health engagement	34
Dipeptidyl-peptidase IV inhibitor–associated bullous pemphigoid: A systematic review and meta-analysis	34
Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients	34
The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanism	33
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis	33
Fibrosing alopecia in a pattern distribution	33
Consulting ChatGPT: Ethical dilemmas in language model artificial intelligence	33
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)	33
Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison	33
The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study	32
Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases	32
Association between hydrochlorothiazide and the risk of in situ and invasive squamous cell skin carcinoma and basal cell carcinoma: A population-based case-control study	32
Tofacitinib in the treatment of lichen planopilaris: A retrospective review	32
Diffuse variants of scalp lichen planopilaris: Clinical, trichoscopic, and histopathologic features of 40 patients	32
Disorders of hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders	32
Janus kinase inhibitors in dermatology: Part II. A comprehensive review	31
Bullous pemphigoid after anti–programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes	31
Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis	31
Reflectance confocal microscopy	31
The impact of the COVID-19 pandemic on the presentation status of newly diagnosed melanoma: A single institution experience	30
Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients	30
Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part I: Clinical and histologic features and diagnosis	30
Bidirectional relationship between atopic dermatitis and inflammatory bowel disease: A systematic review and meta-analysis	30
Cutaneous adverse reactions to anti–PD-1 treatment—A systematic review	30
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, pl	29
Artificial intelligence–derived dermatology case reports are indistinguishable from those written by humans: A single-blinded observer study	29
Eruptions and related clinical course among 296 hospitalized adults with confirmed COVID-19	29

A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis	29
The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo	29
Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry	29
Five-year survival in patients with nodular and superficial spreading melanomas in the US population	29
Narrow excision margins are appropriate for Merkel cell carcinoma when combined with adjuvant radiation: Analysis of 188 cases of localized disease and proposed management algorithm	29
Development of the alopecia areata scale for clinical use: Results of an academic–industry collaborative effort	29
COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases	28
Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice	28
Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey	28
Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis	28
Cause or cure? Review of dupilumab and alopecia areata	28
Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-con	28
Deep learning for dermatologists: Part II. Current applications	28
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results	28
Modifiable lifestyle and environmental factors associated with onset of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational studies	28
Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology	28
Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis	28
Expansion of asynchronous teledermatology during the COVID-19 pandemic	28
Risk factors for frontal fibrosing alopecia: A case-control study in a multiracial population	27
Improved survival in women versus men with merkel cell carcinoma	27
Isotretinoin and the risk of psychiatric disturbances: A global study shedding new light on a debatable story	27
Artificial intelligence in the detection of skin cancer	27
Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak	27
Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study	27
Patient and physician perspectives on teledermatology at an academic dermatology department amid the COVID-19 pandemic	27
Exposure to air pollution and incidence of atopic dermatitis in the general population: A national population-based retrospective cohort study	27
Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: A systematic review and meta-analysis	27
Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United State	27
Understanding the impact of teledermatology on no-show rates and health care accessibility: A retrospective chart review	26
Characterizing the effects of radiation dermatitis on quality of life: A prospective survey-based study	26
Skin cancer: Primary, secondary, and tertiary prevention. Part II.	26
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial	26
One-year real-world clinical effectiveness, safety, and laboratory safety of dupilumab in Japanese adult patients with atopic dermatitis: A single-center retrospective study	26
Use of teledermatology by dermatology hospitalists is effective in the diagnosis and management of inpatient disease	26
Hidradenitis suppurativa in pediatric patients	26
Oral forms of secondary syphilis: An illustration of the pitfalls set by the great imitator	26
Psoriasis and hidradenitis suppurativa: A large-scale population-based study	26
Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study	26
Clinical, histopathologic, immunohistochemical, and electron microscopic findings in cutaneous monkeypox: A multicenter retrospective case series in Spain	26
Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized	26
Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada	26
Antimicrobials and resistance part II: Antifungals, antivirals, and antiparasitics	26
A dermatologic assessment of 101 mpox (monkeypox) cases from 13 countries during the 2022 outbreak: Skin lesion morphology, clinical course, and scarring	26
The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication	25
Gender and racial underrepresentation in academic dermatology positions in the United States: A retrospective, cross-sectional study from 2007 to 2018	25
Pediatric allergic contact dermatitis. Part I: Clinical features and common contact allergens in children	25
Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies	25
Dietary supplements in dermatology: A review of the evidence for zinc, biotin, vitamin D, nicotinamide, and Polypodium	25
Racial and ethnic health disparities in dermatology in the United States. Part 2: Disease-specific epidemiology, characteristics, management, and outcomes	25
Male balding is a major risk factor for severe COVID-19	25
Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial	25
Effect of onychomycosis and treatment on patient-reported quality-of-life outcomes: A systematic review	24
Skin reactions to COVID-19 vaccines: An American Academy of Dermatology/International League of Dermatological Societies registry update on reaction location and COVID vaccine type	24
Cutaneous interaction with visible light: What do we know?	24
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist	24
Contact dermatitis associated with preservatives: Retrospective analysis of North American Contact Dermatitis Group data, 1994 through 2016	24
Alpha-1 antitrypsin deficiency–associated panniculitis	24
Disorders of hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentation	24
Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: A multicenter, randomized, double-blind, double-dummy, pilot study	24
Eyelid dermatitis in patients referred for patch testing: Retrospective analysis of North American Contact Dermatitis Group data, 1994-2016	24
Risk of psoriasis according to body mass index: A retrospective cohort analysis	23
Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study	23
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis	23
A randomized comparative study of the effect of betamethasone oral mini-pulse therapy versus oral azathioprine in progressive nonsegmental vitiligo	23
Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series	23
Metabolic syndrome and its factors are associated with noncalcified coronary burden in psoriasis: An observational cohort study	23
Photoprotection for skin of all color: Consensus and clinical guidance from an expert panel	23
Misconceptions of photoprotection in skin of color	23
Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor–induced dermatologic adverse events	23
Association between vaccination and autoimmune bullous diseases: A systematic review	23
The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris	22
Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score–matched cohort study	22
Associations of combined lifestyle and genetic risks with incident psoriasis: A prospective cohort study among UK Biobank participants of European ancestry	22
Treatment of lichen planopilaris with baricitinib: A retrospective study	22
Bicalutamide: A potential new oral antiandrogenic drug for female pattern hair loss	22
Real-world comorbidities of atopic dermatitis in the US adult ambulatory population	22
Long-term outcomes of Mohs micrographic surgery for invasive melanoma of the trunk and proximal portion of the extremities	22
Application of machine learning to determine top predictors of noncalcified coronary burden in psoriasis: An observational cohort study	22
Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis	22
ChatGPT for healthcare providers and patients: Practical implications within dermatology	22
Psoriasis is not associated with cognition, brain imaging markers, and risk for dementia: The Rotterdam Study	22
Characterizing dupilumab facial redness in children and adolescents: A single-institution retrospective chart review	22
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study	22
Efficacy and safety of very-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia	22
New-onset depression among children, adolescents, and adults with hidradenitis suppurativa	22
Skin of color representation in medical education: An analysis of popular preparatory materials used for United States Medical Licensing Examinations	22
Belimumab for refractory manifestations of cutaneous lupus: A multicenter, retrospective observational study of 16 patients	22
Pediatric androgenetic alopecia: A review	22
Autoimmune and dermatologic conditions associated with lichen sclerosus	21
Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series	21
Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: A dual-center retrospective study	21
DISCERN scores of YouTube information on eczema treatments	21
Risk of new-onset inflammatory bowel disease among patients with acne vulgaris exposed to isotretinoin	21
Oral minoxidil improves background hair thickness in lichen planopilaris	21
Standardizing serial photography for assessing and monitoring vitiligo: A core set of international recommendations for essential clinical and technical specifications	21